Loading...

BCRX BIOCRYST PHARMACEUTICALS INC Investments/Divestments 8-K Filing

BCRY

BCRX

BIOCRYST PHARMACEUTICALS INC

(BCRX)

2023 8-K

Show Summary

Summary

Financial Statements

Stock Purchase Agreement

Clinical Trials

New Product Launches

Financial Statements

Management Changes

CFO Resignation

Financial Results

Investor Conference

Q3 Financial Results

Trial Enrollment

Financial Results and Busin...

Annual Meeting Approval

Financial Results Announcement

Financial Results Announcement

By-Laws Amendment

Financial Results

Departure of Directors

Commercialization Agreement...

Regulation FD Disclosure

License Agreement for Avora...

Financial Results Announcement

Clinical Trial Enrollment

Financial Results and Busin...

Annual Meeting Approval of ...

Financial Results and Busin...

External Links:

BioCryst Pharmaceuticals has updated its commercialization agreement with Torii Pharmaceutical for ORLADEYO in Japan, with BioCryst now responsible for commercial promotion activities and receiving a 20% royalty on sales below a threshold and an 80% royalty on sales above the threshold.

AI Assistant

BIOCRYST PHARMACEUTICALS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.